dorzolamide and Retinal-Diseases

Dome-shaped macula (DSM) is characterised by a convex anterior bulging of the macular area. It can further get complicated by accumulation of subretinal fluid (SRF). Foveal cysts that are bilateral, in a setting of DSM, are an entity not yet reported. Management options for DSM with SRF showed variable success. Topical carbonic anhydrase inhibitors (CAIs) have been successful in treating certain macular pathologies. The authors report a rare case of bilateral intraretinal foveal cyst in a myopic child with DSM with favourable response to topical dorzolamide. Topical CAIs may be considered a safe and effective option in such cases.

Topics: Administration, Ophthalmic; Carbonic Anhydrase Inhibitors; Child, Preschool; Cysts; Fluorescein Angiography; Fovea Centralis; Humans; Male; Retinal Diseases; Subretinal Fluid; Sulfonamides; Thiophenes; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity

To report a case of Bietti crystalline retinal dystrophy with cystoid macular edema (CME) that was successfully treated with topical carbonic anhydrase inhibitor.. A 35-year-old otherwise healthy woman, with a known case of Bietti crystalline retinal dystrophy, presented with progressive visual impairment in her right eye for 3 months. The best-corrected visual acuity was 20/50 in the right eye and 20/25 in the left eye. On the basis of the multimodal imaging findings, the patient was diagnosed with Bietti crystalline retinal dystrophy with unilateral CME. Carbonic anhydrase inhibitor therapy twice a day was initiated.. Three months later, visual acuity improved to 20/25 in the right eye, and CME had resolved based on spectral domain ocular coherence tomography findings, although the CME reoccurred after discontinuation of the drug. Three months after resuming the therapy, the best-corrected visual acuity improved back to 20/25.. Cystoid macular edema is one of the main causes of central visual worsening in patients with Bietti crystalline retinal dystrophy. This complication may be resolved with topical carbonic anhydrase inhibitor, resulting in improved anatomical and visual outcomes.

Topics: Administration, Ophthalmic; Adult; Carbonic Anhydrase Inhibitors; Corneal Dystrophies, Hereditary; Female; Humans; Macular Edema; Multimodal Imaging; Ophthalmic Solutions; Retinal Diseases; Sulfonamides; Thiophenes; Visual Acuity

Topics: Administration, Topical; Adult; Aged; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macular Edema; Retinal Diseases; Sulfonamides; Thiophenes; Visual Acuity

Topics: Adult; Carbonic Anhydrase Inhibitors; Cysts; Electroretinography; Eye Proteins; Humans; Male; Mutation, Missense; Polymerase Chain Reaction; Retinal Diseases; Retinoschisis; Sulfonamides; Thiophenes; Tomography, Optical Coherence

To evaluate prospectively whether anti-glaucomatic drugs administered prior to intravitreal anti-vascular endothelial growth factor (VEGF) injection bevacizumab (Avastin,® Roche) or ranibizumab (Lucentis,® Novartis) prevents intraocular hypertension after the injection.. In total, 166 patients (175 eyes) scheduled for intravitreal anti-VEGF injection treatment were prophylactically treated 1 hour before the procedure with Dorzolamide/Timolol (Cosopt,® MSD) (Group 1, 53 eyes) or Brinzolamide/Timolol (Elazop,® Alcon) (Group 2, 84 eyes) or left untreated (Group 3, 29 eyes). Intraocular pressure was analyzed 5 minutes prior to the injection, every 5 minutes for 30 minutes after the procedure, and 1 hour, 1 day, 7 days, and 1 month after the procedure.. The intraocular pressures 5 minutes before the procedure (baseline) for Groups 1, 2, and 3 were 12.06 ± 1.85, 13.98 ± 2.68, and 13.81 ± 2.24 mmHg, respectively. Five and 30 minutes after the procedure, the intraocular pressures of the three groups were 14.12 ± 4.18, 14.87 ± 3.35, and 28.21 ± 3.16 mmHg, respectively, and 10.87 ± 1.58, 14.25 ± 2.43, and 17.48 ± 2.34 mmHg, respectively. For all three groups, the changes relative to baseline 5 and 30 minutes after injection were significant. When the three groups were divided according to whether they received bevacizumab or ranibizumab and the changes in intraocular pressure relative to baseline were analyzed, all six subgroups exhibited significant changes in intraocular pressure 5 and 30 minutes after the procedure.. The prophylactic administration of anti-glaucomatic drugs prior to intravitreal anti-VEGF injection effectively reduced the early intraocular pressure elevation. This approach was also safe and could be performed accurately.

Topics: Administration, Topical; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Drug Therapy, Combination; Female; Humans; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Ranibizumab; Retinal Diseases; Sulfonamides; Thiazines; Thiophenes; Timolol; Tonometry, Ocular; Vascular Endothelial Growth Factor A

The purpose of this study was to evaluate the efficacy of topical dorzolamide 2% eye drops on macular function and thickness in a case of enhanced S-cone syndrome (ESCS). A 24-year-old Asian man with enhanced S-cone syndrome treated with topical dorzolamide in the left eye participated in the study. Examinations performed before and during treatment were included visual acuity (VA), contrast sensitivity measured with briefly presented grating targets (grating CS) and the Pelli-Robson chart (P-R CS), microperimetry (MP), and spectral-domain optical coherence tomography (SD-OCT). Following 4 months of treatment, the mean thickness of the central 1-mm foveal subfield of the left eye, as measured by SD-OCT, decreased from 551 to 242 μm. Mean MP sensitivity within the central 12 degrees (28 points) increased from 9.4 dB at baseline to 11.2 dB. Although Pelli-Robson contrast sensitivity improved only minimally in the left eye, grating contrast sensitivity improved by more than a factor of two. Mean log MAR VA was 0.22 OD and 1.00 OS (at baseline), which improved to 0.10 OD and 0.66 OS after 4 months of treatment. The results indicate that in our patient with enhanced S-cone syndrome, treatment with topical dorzolamide was effective in improving macular thickness, VA, microperimetry sensitivity, and grating contrast sensitivity. These measures of retinal structure and function are sensitive tools for evaluating the effects of treatment in enhanced S-cone syndrome patients with cystoid macular edema. Further investigation is warranted to assess the relationships among visual performance for daily activities, visual sensitivity, and macular thickness.

Topics: Administration, Topical; Carbonic Anhydrase Inhibitors; Contrast Sensitivity; Humans; Macular Edema; Male; Retinal Cone Photoreceptor Cells; Retinal Diseases; Sulfonamides; Syndrome; Thiophenes; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Visual Field Tests; Young Adult

Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Female; Glaucoma, Angle-Closure; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Levobunolol; Macula Lutea; Middle Aged; Ocular Hypotension; Ophthalmic Solutions; Prednisolone; Prodrugs; Pseudophakia; Recurrence; Retinal Diseases; Sulfonamides; Thiophenes; Ultrasonography